Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 1
1996 1
2003 1
2006 1
2007 1
2012 2
2014 1
2015 1
2016 2
2017 5
2018 3
2019 2
2020 3
2021 3
2022 1
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Oral versus Intravenous Antibiotics for Bone and Joint Infection.
Li HK, Rombach I, Zambellas R, Walker AS, McNally MA, Atkins BL, Lipsky BA, Hughes HC, Bose D, Kümin M, Scarborough C, Matthews PC, Brent AJ, Lomas J, Gundle R, Rogers M, Taylor A, Angus B, Byren I, Berendt AR, Warren S, Fitzgerald FE, Mack DJF, Hopkins S, Folb J, Reynolds HE, Moore E, Marshall J, Jenkins N, Moran CE, Woodhouse AF, Stafford S, Seaton RA, Vallance C, Hemsley CJ, Bisnauthsing K, Sandoe JAT, Aggarwal I, Ellis SC, Bunn DJ, Sutherland RK, Barlow G, Cooper C, Geue C, McMeekin N, Briggs AH, Sendi P, Khatamzas E, Wangrangsimakul T, Wong THN, Barrett LK, Alvand A, Old CF, Bostock J, Paul J, Cooke G, Thwaites GE, Bejon P, Scarborough M; OVIVA Trial Collaborators. Li HK, et al. N Engl J Med. 2019 Jan 31;380(5):425-436. doi: 10.1056/NEJMoa1710926. N Engl J Med. 2019. PMID: 30699315 Free PMC article. Clinical Trial.
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.
Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, Oguchi G, Ryan P, Nielsen BU, Brown M, Hidalgo A, Sachdeva Y, Mittal S, Osiyemi O, Skarbinski J, Juneja K, Hyland RH, Osinusi A, Chen S, Camus G, Abdelghany M, Davies S, Behenna-Renton N, Duff F, Marty FM, Katz MJ, Ginde AA, Brown SM, Schiffer JT, Hill JA; GS-US-540-9012 (PINETREE) Investigators. Gottlieb RL, et al. N Engl J Med. 2022 Jan 27;386(4):305-315. doi: 10.1056/NEJMoa2116846. Epub 2021 Dec 22. N Engl J Med. 2022. PMID: 34937145 Free PMC article. Clinical Trial.
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19.
Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, Ogishi M, Sabli IKD, Hodeib S, Korol C, Rosain J, Bilguvar K, Ye J, Bolze A, Bigio B, Yang R, Arias AA, Zhou Q, Zhang Y, Onodi F, Korniotis S, Karpf L, Philippot Q, Chbihi M, Bonnet-Madin L, Dorgham K, Smith N, Schneider WM, Razooky BS, Hoffmann HH, Michailidis E, Moens L, Han JE, Lorenzo L, Bizien L, Meade P, Neehus AL, Ugurbil AC, Corneau A, Kerner G, Zhang P, Rapaport F, Seeleuthner Y, Manry J, Masson C, Schmitt Y, Schlüter A, Le Voyer T, Khan T, Li J, Fellay J, Roussel L, Shahrooei M, Alosaimi MF, Mansouri D, Al-Saud H, Al-Mulla F, Almourfi F, Al-Muhsen SZ, Alsohime F, Al Turki S, Hasanato R, van de Beek D, Biondi A, Bettini LR, D'Angio' M, Bonfanti P, Imberti L, Sottini A, Paghera S, Quiros-Roldan E, Rossi C, Oler AJ, Tompkins MF, Alba C, Vandernoot I, Goffard JC, Smits G, Migeotte I, Haerynck F, Soler-Palacin P, Martin-Nalda A, Colobran R, Morange PE, Keles S, Çölkesen F, Ozcelik T, Yasar KK, Senoglu S, Karabela ŞN, Rodríguez-Gallego C, Novelli G, Hraiech S, Tandjaoui-Lambiotte Y, Duval X, Laouénan C; COVID-STORM Clinicians; COVID Clinicians; Imagine COVID Group; French COVID Cohort Study Group; CoV-Contact Cohort… See abstract for full author list ➔ Zhang Q, et al. Science. 2020 Oct 23;370(6515):eabd4570. doi: 10.1126/science.abd4570. Epub 2020 Sep 24. Science. 2020. PMID: 32972995 Free PMC article.
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.
McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, Reid CM, Lockery JE, Kirpach B, Storey E, Shah RC, Williamson JD, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Orchard SG, Trevaks RE, Beilin LJ, Johnston CI, Ryan J, Radziszewska B, Jelinek M, Malik M, Eaton CB, Brauer D, Cloud G, Wood EM, Mahady SE, Satterfield S, Grimm R, Murray AM; ASPREE Investigator Group. McNeil JJ, et al. N Engl J Med. 2018 Oct 18;379(16):1509-1518. doi: 10.1056/NEJMoa1805819. Epub 2018 Sep 16. N Engl J Med. 2018. PMID: 30221597 Free PMC article. Clinical Trial.
Multiaperture g-C(3)N(4)@SiO(2) to activate peroxydisulfate via visible light for efficient Rhodamine B removal.
Yao S, Wang B, Cao X. Yao S, et al. Environ Sci Pollut Res Int. 2023 Jun;30(30):75500-75510. doi: 10.1007/s11356-023-27782-9. Epub 2023 May 23. Environ Sci Pollut Res Int. 2023. PMID: 37219775
A Fenton-like process was constructed and showed great potential to remove organic pollutants using visible-light-assisted PDS activation. The g-C(3)N(4)@SiO(2) was synthesized via thermo-polymerization, and characterized using powder X-ray diffraction (XRD), scanni …
A Fenton-like process was constructed and showed great potential to remove organic pollutants using visible-light-assisted PDS activation. T …
TiO(2)/g-C(3)N(4)/SO(3)H(IL): Unique Usage of Ionic Liquid-Based Sulfonic Acid as an Efficient Photocatalyst for Visible-Light-Driven Preparation of 5-HMF from Cellulose and Glucose.
Nayebi M, Faraji A, Bahadoran A, Othman ZJ, Arghavani S, Kargar PG, Sajjadinezhad SM, Varma RS. Nayebi M, et al. ACS Appl Mater Interfaces. 2023 Feb 15;15(6):8054-8065. doi: 10.1021/acsami.2c20480. Epub 2023 Jan 31. ACS Appl Mater Interfaces. 2023. PMID: 36719302
Herein, the fabrication of a morphologically unique acidic catalyst encompassing a two-dimensional (2D) TiO(2)/g-C(3)N(4) heterojunction feature is described for the generation of 5-hydroxymethylfurfural (5-HMF), which exploits the acidic/ionic liquid (IL) bifunctio …
Herein, the fabrication of a morphologically unique acidic catalyst encompassing a two-dimensional (2D) TiO(2)/g-C(3)N(4) hete …
The Collision of COVID-19 and the U.S. Health System.
Bornstein SS, Mire RD, Barrett ED, Moyer DV, Cooney TG. Bornstein SS, et al. Ann Intern Med. 2020 Sep 15;173(6):484-485. doi: 10.7326/M20-1851. Epub 2020 Jun 2. Ann Intern Med. 2020. PMID: 32484741 Free PMC article.
Insights Into the Oral Microbiome and Barrett's Esophagus Early Detection: A Narrative Review.
Zhang Z, Curran G, Altinok Dindar D, Wu Y, Wu H, Sharpton T, Zhao L, Lieberman D, Otaki F. Zhang Z, et al. Clin Transl Gastroenterol. 2021 Aug 26;12(9):e00390. doi: 10.14309/ctg.0000000000000390. Clin Transl Gastroenterol. 2021. PMID: 34446641 Free PMC article. Review.
Barrett's esophagus (BE) prevalence has increased steadily over the past several decades and continues to be the only known precursor of esophageal adenocarcinoma. ...
Barrett's esophagus (BE) prevalence has increased steadily over the past several decades and continues to be the only known pr
A Tissue Systems Pathology Test Outperforms the Standard-of-Care Variables in Predicting Progression in Patients With Barrett's Esophagus.
Davison JM, Goldblum JR, Duits LC, Khoshiwal AM, Bergman JJ, Falk GW, Diehl DL, Khara HS, Smolko C, Arora M, Siegel JJ, Critchley-Thorne RJ, Thota PN. Davison JM, et al. Clin Transl Gastroenterol. 2023 Nov 1;14(11):e00631. doi: 10.14309/ctg.0000000000000631. Clin Transl Gastroenterol. 2023. PMID: 37622544 Free PMC article.
INTRODUCTION: Objective risk stratification is needed for patients with Barrett's esophagus (BE) to enable risk-aligned management to improve health outcomes. ...The TSP-9 test identified 57% of progressors with nondysplastic Barrett's esophagus (NDBE) …
INTRODUCTION: Objective risk stratification is needed for patients with Barrett's esophagus (BE) to enable risk-aligned manage …
Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms.
Horikawa I, Barrett JC. Horikawa I, et al. Carcinogenesis. 2003 Jul;24(7):1167-76. doi: 10.1093/carcin/bgg085. Epub 2003 May 22. Carcinogenesis. 2003. PMID: 12807729 Review.
Several transcription factors, including oncogene products (e.g. c-Myc) and tumor suppressor gene products (e.g. WT1 and p53), are able to control hTERT transcription when over-expressed, although it remains to be determined whether a cancer-associated alteration of …
Several transcription factors, including oncogene products (e.g. c-Myc) and tumor suppressor gene products (e.g. WT1 and p53), …
30 results